8-K: AbbVie Reports Strong Second Quarter Results, Raises Full-Year EPS Guidance

AbbVie's second-quarter results exceeded expectations, driven by strong performance in its ex-Humira portfolio, leading to an increase in the company's full-year adjusted diluted EPS guidance.

Summary

• AbbVie announced its financial results for the second quarter of 2024, reporting a diluted EPS of $0.77 on a GAAP basis, a decrease of 32.5 percent, and an adjusted diluted EPS of $2.65, a decrease of 8.9 percent.
• These results include an unfavorable impact of $0.52 per share related to acquired IPR&D and milestones expense.
• The company's net revenues for the quarter were $14.462 billion, an increase of 4.3 percent on a reported basis and 5.6 percent on an operational basis.
• Global net revenues from the immunology portfolio were $6.971 billion, with Humira revenues at $2.814 billion, Skyrizi at $2.727 billion, and Rinvoq at $1.430 billion.
• The oncology portfolio generated $1.634 billion in net revenues, while the neuroscience portfolio brought in $2.162 billion.
• The aesthetics portfolio had net revenues of $1.390 billion.
• AbbVie has raised its 2024 adjusted diluted EPS guidance range from $10.61 $10.81 to $10.71 $10.91, which includes an unfavorable impact of $0.60 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter 2024.

Sentiment

Score: 8

Explanation: The sentiment is positive due to strong revenue growth in key areas, raised EPS guidance, and strategic acquisitions. However, the decline in Humira sales and the delay in ABBV-951 approval temper the overall optimism.

Positives

• AbbVie's business performed exceptionally well in the second quarter, exceeding expectations.
• The ex-Humira growth platform is showing significant momentum.
• Skyrizi and Rinvoq are experiencing strong revenue growth, offsetting the decline in Humira sales.
• The neuroscience portfolio is demonstrating robust growth.
• The company's pipeline is progressing well with recent acquisitions and regulatory approvals.
• The adjusted diluted EPS guidance for 2024 has been raised.

Negatives

• GAAP diluted EPS decreased by 32.5 percent compared to the same quarter last year.
• Adjusted diluted EPS decreased by 8.9 percent compared to the same quarter last year.
• Humira's global net revenues decreased by 29.8 percent on a reported basis.
• The company experienced an unfavorable impact of $0.52 per share related to acquired IPR&D and milestones expense in the second quarter.
• Juvederm net revenues decreased by 6.8 percent on a reported basis.

Risks

• The company faces risks related to the proposed acquisition of Cerevel Therapeutics, including the possibility that the acquisition may not be completed.
• There are risks associated with realizing the anticipated benefits of the proposed acquisition.
• The company faces challenges related to intellectual property, competition, and the research and development process.
• Adverse litigation or government action could impact the company's performance.
• Changes to laws and regulations applicable to the industry could pose risks.

Future Outlook

AbbVie is raising its adjusted diluted EPS guidance for the full year 2024 from $10.61 $10.81 to $10.71 $10.91, which includes an unfavorable impact of $0.60 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter 2024. The company's 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the second quarter of 2024, as both cannot be reliably forecasted.

Management Comments

• Our business continues to perform exceptionally well, with second quarter results meaningfully ahead of our expectations, said Robert A. Michael, chief executive officer, AbbVie.
• Based upon the significant momentum of our ex-Humira growth platform, our continued investments in the business and our pipeline progress, we are very well positioned to deliver our top-tier long-term outlook.

Industry Context

AbbVie's results reflect the ongoing shift in the pharmaceutical industry as companies adapt to patent expirations and develop new growth drivers. The strong performance of Skyrizi and Rinvoq highlights the importance of innovative therapies in the immunology space, while the growth in the neuroscience portfolio indicates a focus on expanding into new therapeutic areas. The acquisitions of Landos Biopharma and Celsius Therapeutics demonstrate a strategic move to bolster the pipeline with novel assets.

Comparison to Industry Standards

• AbbVie's performance in the immunology space, particularly with Skyrizi and Rinvoq, is comparable to other major pharmaceutical companies that have successfully launched new biologics to offset declines in older products. For example, companies like Johnson & Johnson with Stelara and Tremfya have shown similar growth trajectories in the immunology market.
• The decline in Humira sales is consistent with industry expectations as biosimilars enter the market, similar to what has been observed with other blockbuster drugs facing generic competition.
• AbbVie's growth in the neuroscience portfolio is in line with the broader trend of increased investment in neurological and psychiatric treatments, as seen with companies like Biogen and Eli Lilly.
• The aesthetics portfolio's performance is mixed, with Botox Cosmetic showing growth while Juvederm is declining, which is similar to trends seen in the broader aesthetics market where some products gain popularity while others lose market share.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the raised EPS guidance and strong performance in key growth areas.
• Employees may experience changes due to the recent acquisitions and management transition.
• Customers will benefit from the approval of new therapies and the expansion of AbbVie's product portfolio.
• Suppliers and creditors will be impacted by the company's financial performance and strategic decisions.

Next Steps

• AbbVie will continue to work with the FDA to bring ABBV-951 to patients in the U.S. as quickly as possible.
• The company will present full data from the PICCOLO study at a future medical meeting.
• AbbVie will continue to advance its pipeline and seek regulatory approvals for new indications.

Key Dates

Keywords

AbbVie, Financial Results, Second Quarter, EPS, Revenue, Humira, Skyrizi, Rinvoq, Immunology, Oncology, Neuroscience, Aesthetics, Acquisition, FDA Approval, Guidance